menu search

Madrigal’s stock rallies about 200% after sharing positive data about its NASH treatment candidate

Shares of Madrigal Pharmaceuticals Inc. soared 209.6% in premarket trading on Monday after the company shared positive data from a pivotal Phase 3 clinical trial assessing its experimental treatment for nonalcoholic steatohepatitis (NASH) with liver fibrosis. Madrigal said it is aiming to get an accelerated approval for the drug, resmetirom. There are no approved treatments […] The post Madrigal’s stock rallies about 200% after sharing positive data about its NASH treatment candidate appeared fi... Read More
Posted: Dec 19 2022, 13:07
Author Name: forextv
Views: 103033

Search within

Pages Search Results: